Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling

Jackie Wanjala, Barry S. Taylor, Caren Chapinski, Haley Hieronymus, John Wongvipat, Yu Chen, Gouri J. Nanjangud, Nikolaus Schultz, Yingqiu Xie, Shenji Liu, Wenfu Lu, Qing Yang, Chris Sander, Zhenbang Chen, Charles L. Sawyers, Brett S. Carver

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Copy-number alterations (CNA) are among the most common molecular events in human prostate cancer genomes and are associated with worse prognosis. Identification of the oncogenic drivers within these CNAs is challenging due to the broad nature of these genomic gains or losses which can include large numbers of genes within a given region. Here, we profiled the genomes of four genetically engineered mouse prostate cancer models that reflect oncogenic events common in human prostate tumors, with the goal of integrating these data with human prostate cancer datasets to identify shared molecular events. Met was amplified in 67% of prostate tumors from Pten p53 prostate conditional null mice and in approximately 30% of metastatic human prostate cancer specimens, often in association with loss of PTEN and TP53. In murine tumors with Met amplification, Met copy-number gain and expression was present in some cells but not others, revealing intratumoral heterogeneity. Forced MET overexpression in non-MET-amplified prostate tumor cells activated PI3K and MAPK signaling and promoted cell proliferation and tumor growth, whereas MET kinase inhibition selectively impaired the growth of tumors with Met amplification. However, the impact of MET inhibitor therapy was compromised by the persistent growth of non-Met-amplified cells within Met-amplified tumors. These findings establish the importance of MET in prostate cancer progression but reveal potential limitations in the clinical use of MET inhibitors in late-stage prostate cancer.

Original languageEnglish
Pages (from-to)278-288
Number of pages11
JournalMolecular Cancer Therapeutics
Volume14
Issue number1
DOIs
Publication statusPublished - Jan 1 2015
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Prostate
Neoplasms
Growth
Genome
Phosphatidylinositol 3-Kinases
Phosphotransferases
Cell Proliferation
Genes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wanjala, J., Taylor, B. S., Chapinski, C., Hieronymus, H., Wongvipat, J., Chen, Y., ... Carver, B. S. (2015). Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling. Molecular Cancer Therapeutics, 14(1), 278-288. https://doi.org/10.1158/1535-7163.MCT-14-0542-T

Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling. / Wanjala, Jackie; Taylor, Barry S.; Chapinski, Caren; Hieronymus, Haley; Wongvipat, John; Chen, Yu; Nanjangud, Gouri J.; Schultz, Nikolaus; Xie, Yingqiu; Liu, Shenji; Lu, Wenfu; Yang, Qing; Sander, Chris; Chen, Zhenbang; Sawyers, Charles L.; Carver, Brett S.

In: Molecular Cancer Therapeutics, Vol. 14, No. 1, 01.01.2015, p. 278-288.

Research output: Contribution to journalArticle

Wanjala, J, Taylor, BS, Chapinski, C, Hieronymus, H, Wongvipat, J, Chen, Y, Nanjangud, GJ, Schultz, N, Xie, Y, Liu, S, Lu, W, Yang, Q, Sander, C, Chen, Z, Sawyers, CL & Carver, BS 2015, 'Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling', Molecular Cancer Therapeutics, vol. 14, no. 1, pp. 278-288. https://doi.org/10.1158/1535-7163.MCT-14-0542-T
Wanjala, Jackie ; Taylor, Barry S. ; Chapinski, Caren ; Hieronymus, Haley ; Wongvipat, John ; Chen, Yu ; Nanjangud, Gouri J. ; Schultz, Nikolaus ; Xie, Yingqiu ; Liu, Shenji ; Lu, Wenfu ; Yang, Qing ; Sander, Chris ; Chen, Zhenbang ; Sawyers, Charles L. ; Carver, Brett S. / Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling. In: Molecular Cancer Therapeutics. 2015 ; Vol. 14, No. 1. pp. 278-288.
@article{be02661aa45e43ddb56a0347f9aad3ae,
title = "Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling",
abstract = "Copy-number alterations (CNA) are among the most common molecular events in human prostate cancer genomes and are associated with worse prognosis. Identification of the oncogenic drivers within these CNAs is challenging due to the broad nature of these genomic gains or losses which can include large numbers of genes within a given region. Here, we profiled the genomes of four genetically engineered mouse prostate cancer models that reflect oncogenic events common in human prostate tumors, with the goal of integrating these data with human prostate cancer datasets to identify shared molecular events. Met was amplified in 67{\%} of prostate tumors from Pten p53 prostate conditional null mice and in approximately 30{\%} of metastatic human prostate cancer specimens, often in association with loss of PTEN and TP53. In murine tumors with Met amplification, Met copy-number gain and expression was present in some cells but not others, revealing intratumoral heterogeneity. Forced MET overexpression in non-MET-amplified prostate tumor cells activated PI3K and MAPK signaling and promoted cell proliferation and tumor growth, whereas MET kinase inhibition selectively impaired the growth of tumors with Met amplification. However, the impact of MET inhibitor therapy was compromised by the persistent growth of non-Met-amplified cells within Met-amplified tumors. These findings establish the importance of MET in prostate cancer progression but reveal potential limitations in the clinical use of MET inhibitors in late-stage prostate cancer.",
author = "Jackie Wanjala and Taylor, {Barry S.} and Caren Chapinski and Haley Hieronymus and John Wongvipat and Yu Chen and Nanjangud, {Gouri J.} and Nikolaus Schultz and Yingqiu Xie and Shenji Liu and Wenfu Lu and Qing Yang and Chris Sander and Zhenbang Chen and Sawyers, {Charles L.} and Carver, {Brett S.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1158/1535-7163.MCT-14-0542-T",
language = "English",
volume = "14",
pages = "278--288",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling

AU - Wanjala, Jackie

AU - Taylor, Barry S.

AU - Chapinski, Caren

AU - Hieronymus, Haley

AU - Wongvipat, John

AU - Chen, Yu

AU - Nanjangud, Gouri J.

AU - Schultz, Nikolaus

AU - Xie, Yingqiu

AU - Liu, Shenji

AU - Lu, Wenfu

AU - Yang, Qing

AU - Sander, Chris

AU - Chen, Zhenbang

AU - Sawyers, Charles L.

AU - Carver, Brett S.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Copy-number alterations (CNA) are among the most common molecular events in human prostate cancer genomes and are associated with worse prognosis. Identification of the oncogenic drivers within these CNAs is challenging due to the broad nature of these genomic gains or losses which can include large numbers of genes within a given region. Here, we profiled the genomes of four genetically engineered mouse prostate cancer models that reflect oncogenic events common in human prostate tumors, with the goal of integrating these data with human prostate cancer datasets to identify shared molecular events. Met was amplified in 67% of prostate tumors from Pten p53 prostate conditional null mice and in approximately 30% of metastatic human prostate cancer specimens, often in association with loss of PTEN and TP53. In murine tumors with Met amplification, Met copy-number gain and expression was present in some cells but not others, revealing intratumoral heterogeneity. Forced MET overexpression in non-MET-amplified prostate tumor cells activated PI3K and MAPK signaling and promoted cell proliferation and tumor growth, whereas MET kinase inhibition selectively impaired the growth of tumors with Met amplification. However, the impact of MET inhibitor therapy was compromised by the persistent growth of non-Met-amplified cells within Met-amplified tumors. These findings establish the importance of MET in prostate cancer progression but reveal potential limitations in the clinical use of MET inhibitors in late-stage prostate cancer.

AB - Copy-number alterations (CNA) are among the most common molecular events in human prostate cancer genomes and are associated with worse prognosis. Identification of the oncogenic drivers within these CNAs is challenging due to the broad nature of these genomic gains or losses which can include large numbers of genes within a given region. Here, we profiled the genomes of four genetically engineered mouse prostate cancer models that reflect oncogenic events common in human prostate tumors, with the goal of integrating these data with human prostate cancer datasets to identify shared molecular events. Met was amplified in 67% of prostate tumors from Pten p53 prostate conditional null mice and in approximately 30% of metastatic human prostate cancer specimens, often in association with loss of PTEN and TP53. In murine tumors with Met amplification, Met copy-number gain and expression was present in some cells but not others, revealing intratumoral heterogeneity. Forced MET overexpression in non-MET-amplified prostate tumor cells activated PI3K and MAPK signaling and promoted cell proliferation and tumor growth, whereas MET kinase inhibition selectively impaired the growth of tumors with Met amplification. However, the impact of MET inhibitor therapy was compromised by the persistent growth of non-Met-amplified cells within Met-amplified tumors. These findings establish the importance of MET in prostate cancer progression but reveal potential limitations in the clinical use of MET inhibitors in late-stage prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84921515970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921515970&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-14-0542-T

DO - 10.1158/1535-7163.MCT-14-0542-T

M3 - Article

VL - 14

SP - 278

EP - 288

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 1

ER -